CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences 
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links 
Anthropic Eyes $350 Billion Valuation as AI Funding and Share Sale Accelerate 
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
Boeing Signals Progress on Delayed 777X Program With Planned April First Flight 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
Instagram Outage Disrupts Thousands of U.S. Users 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO 
Australian Scandium Project Backed by Richard Friedland Poised to Support U.S. Critical Minerals Stockpile 
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment 
AMD Shares Slide Despite Earnings Beat as Cautious Revenue Outlook Weighs on Stock 
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
DENVER, Feb. 28, 2017 -- The world’s leading high-quality cannabidiol (CBD) hemp oil brand, Elixinol, announces the availability of its product line in Brazil, making organic CBD available to over 205 million people in Latin America’s most populous country.
“For sufferers of conditions such as epilepsy and multiple sclerosis, Brazil’s recognition of CBD’s therapeutic benefits is an important step towards functional, fulfilling lives and Elixinol is proud to be able to be part of the therapy for treating these very serious conditions,” said Paul Benhaim, CEO of Elixinol.
Although its relationship with cannabis remains complicated, Brazil joins countries like Japan, whose perceptions are shifting as they once again recognize the benefits of hemp.
Doctors in Brazil may prescribe CBD, including Elixinol, for treatment of intractable seizures. In 2014 Federal Medical Council of Brazil)(CFM) officially authorized the compassionate use of CBD for the treatment of intractable epilepsy in children and adolescents.
It is estimated that over 2 million Brazilians suffer from epileptic seizures and over 675,000 suffer from intractable seizures.
In 2015, ANVISA (National Agency of Sanitary Surveillance) defined the procedures for the importation of CBD products into Brazil by individuals, hospitals and health insurance companies, as published in the Resolução da Diretoria Colegiada (RDC) 17/2015.
In 2016, Elixinol hemp oil was included in ANVISA’s list of most frequently imported products and will have a simpler authorization process, as stated in the health agency’s RDC 128/2016.
“It’s an honor to be a working with the medical community, the people and the government of Brazil to bring high-quality, organic hemp relief to the sufferers whose doctors see CBD as a treatment option,” said Dr. Philip Blair, MD, Elixinol Medical Advisor.
About Elixinol:
Colorado-based Elixinol, founded by Paul Benhaim, hemp entrepreneur since 1991, is widely regarded as one of the most influential CBD brands in the world. With a proven track record of growing and manufacturing high-quality hemp, Elixinol also conducts rigorous laboratory testing and quality control. A global leader in hemp distribution, Elixinol provides CBD products globally in the United States, Japan, Brazil, Puerto Rico and the UK. More information available at Elixinol.com.
Media Contact: Chris Husong Elixinol 408-420-8890 (m) [email protected]
